Physician profile
Edward A Reece
NPI 1235253576
$1,554.29
in general payments reported to CMS, 2019-2025
14 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $89.64 · 2021: $290 · 2022: $96.91 · 2023: $31.35 · 2024: $392 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $277.38 | 2020-2025 | Evenity, Repatha, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.96 | 2019-2025 | Jardiance |
| Abbott Laboratories | $223.59 | 2019-2024 | Freestyle Libre 3 |
| Allergan, INC. | $159.01 | 2019-2021 | |
| Abbvie INC. | $140.11 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $119.25 | 2019-2021 | |
| Access Pro Medical, LLC | $91.80 | 2025 | Matriderm |
| Novo Nordisk INC | $82.29 | 2019-2022 | |
| Lilly USA, LLC | $64.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.97 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $42.37 | 2019-2020 | |
| Amarin Pharma, INC. | $35.00 | 2019 | |
| Dexcom, INC. | $15.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Reece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.